Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy
Histone deacetylases (HDACs) influence many cellular processes, including the modulation of signal transducer and activator of transcription activity (STAT) in response to interferon (IFN). To identify genetic markers that help optimize the IL-28B prediction of chronic hepatitis C (CHC) sustained vi...
Gespeichert in:
| Veröffentlicht in: | Genes and immunity 2013-07, Vol.14 (5), p.317-324 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 324 |
|---|---|
| container_issue | 5 |
| container_start_page | 317 |
| container_title | Genes and immunity |
| container_volume | 14 |
| creator | López-Rodríguez, R Hernández-Bartolomé, Á Borque, M J Rodríguez-Muñoz, Y Martín-Vílchez, S Trapero-Marugán, M García-Buey, L Muñoz de Rueda, P Rodrigo, L Vidal-Castiñeira, J R Salmerón, J Moreno-Otero, R Sanz-Cameno, P |
| description | Histone deacetylases (HDACs) influence many cellular processes, including the modulation of signal transducer and activator of transcription activity (STAT) in response to interferon (IFN). To identify genetic markers that help optimize the
IL-28B
prediction of chronic hepatitis C (CHC) sustained virological response (SVR), we evaluated 27 single-nucleotide polymorphisms (SNPs) in
HDAC1–11
. Three SNPs, rs3778216, rs976552 and rs368328 in
HDAC2
,
HDAC3
and
HDAC5
, respectively, were independently associated with SVR (
P |
| doi_str_mv | 10.1038/gene.2013.24 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1419369060</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A341262142</galeid><sourcerecordid>A341262142</sourcerecordid><originalsourceid>FETCH-LOGICAL-c623t-42af0a02523864a0f74ce8f0010a8288d0f8a630b62ac398c93b3d30987f1bf83</originalsourceid><addsrcrecordid>eNp9ksuLFDEQxhtR3IfePEvAiwv2mNck6eM6-BgYUHycQyZdmcnS3WmT9OL896aZ9TGySA6pVH715atQVfWM4AXBTL3ewQALiglbUP6gOidcinrJJX44x0LUXMnmrLpI6QZjIohoHldnlAmyxBKfV92n0B36EMe9T31CfkAlyGEA1IKxkA-dSVDy_RjDLaC8BzRGaL3NvhxvTTcBCg6tNzVVb5ALEdl9DIO3aA-jyT77hFZzWTTj4Un1yJkuwdO7_bL69u7t19WHevPx_Xp1vamtoCzXnBqHDaZLypTgBjvJLShX7GOjqFItdsoIhreCGssaZRu2ZS3DjZKObJ1il9XLo24x_X2ClHXvk4WuMwOEKWnCScNEgwUu6It_0JswxaG401RwIpmQxdN_qKJFKVZc8j_UznSg_eBCjsbOT-trVjBBCZ-1FvdQZbXQe1t-3vmSPym4OikoTIYfeWemlPT6y-dT9tWRtTGkFMHpMfrexIMmWM_joudx0fO4aDo7fn7X17Ttof0N_5qPAtRHIJWrYQfxr8bvE_wJwCbF5w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1412208474</pqid></control><display><type>article</type><title>Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>López-Rodríguez, R ; Hernández-Bartolomé, Á ; Borque, M J ; Rodríguez-Muñoz, Y ; Martín-Vílchez, S ; Trapero-Marugán, M ; García-Buey, L ; Muñoz de Rueda, P ; Rodrigo, L ; Vidal-Castiñeira, J R ; Salmerón, J ; Moreno-Otero, R ; Sanz-Cameno, P</creator><creatorcontrib>López-Rodríguez, R ; Hernández-Bartolomé, Á ; Borque, M J ; Rodríguez-Muñoz, Y ; Martín-Vílchez, S ; Trapero-Marugán, M ; García-Buey, L ; Muñoz de Rueda, P ; Rodrigo, L ; Vidal-Castiñeira, J R ; Salmerón, J ; Moreno-Otero, R ; Sanz-Cameno, P</creatorcontrib><description>Histone deacetylases (HDACs) influence many cellular processes, including the modulation of signal transducer and activator of transcription activity (STAT) in response to interferon (IFN). To identify genetic markers that help optimize the
IL-28B
prediction of chronic hepatitis C (CHC) sustained virological response (SVR), we evaluated 27 single-nucleotide polymorphisms (SNPs) in
HDAC1–11
. Three SNPs, rs3778216, rs976552 and rs368328 in
HDAC2
,
HDAC3
and
HDAC5
, respectively, were independently associated with SVR (
P
<0.05). The addition of these three
HDAC’s
SNPs to the
IL-28B
predictive model (area under the curve (AUC)=0.630) rendered an important improvement of AUC-receiver operating characteristic value (AUC=0.747,
P
=0.021). Chi-squared Automatic Interaction Detector (CHAID) analysis denoted the significance of the rs3778216 C/C genotype in identifying a group of good responders despite carrying
IL-28B
T allele (79.2% of SVR), whereas
HDAC5
G allele characterized a subgroup with poor response rate (25.5%). However,
HDAC3
rs976552 did not display a relevant role for the hierarchical classification of patients. Variables related to SVR in hepatitis C virus genotype 1 (HCV-1) cohort were the same of those obtained for the overall population. Interestingly, in non-HCV-1 patients (
n
=56) the
HDAC2
C/C genotype was the unique predictive variable related to SVR (AUC=0.733,
P
<0.007). Thus, these preliminary results suggest the potential usefulness of combined
IL-28B
and
HDAC
genotyping for the CHC patients’ classification by likelihood of an SVR.</description><identifier>ISSN: 1466-4879</identifier><identifier>EISSN: 1476-5470</identifier><identifier>DOI: 10.1038/gene.2013.24</identifier><identifier>PMID: 23615070</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/208/248 ; 631/208/721 ; 631/250/255/234/2513/1551 ; 631/326/596/2553 ; Adult ; Aged ; Alleles ; Antiviral Agents - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Drug Therapy, Combination ; Female ; Gastroenterology ; Gene Expression ; Gene Frequency ; Genes ; Genetic aspects ; Genetic markers ; Genetic polymorphisms ; Genotype ; Genotype & phenotype ; Genotyping ; HDAC2 protein ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - genetics ; Hepatitis C, Chronic - virology ; Histone deacetylase ; Histone Deacetylases - genetics ; Histones ; Human Genetics ; Humans ; Immune response ; Immunology ; Interferon ; Interferon-alpha - chemistry ; Interferon-alpha - therapeutic use ; Interferons ; Interleukins ; Interleukins - genetics ; Isoenzymes - genetics ; Liver cancer ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; original-article ; Patient outcomes ; Physiological aspects ; Polyethylene Glycols - chemistry ; Polymorphism, Single Nucleotide ; Prediction models ; Prognosis ; Ribavirin - therapeutic use ; Single-nucleotide polymorphism ; Transcription ; Treatment Outcome ; Viral Load - drug effects ; Viral Load - genetics ; Young Adult</subject><ispartof>Genes and immunity, 2013-07, Vol.14 (5), p.317-324</ispartof><rights>Macmillan Publishers Limited 2013</rights><rights>COPYRIGHT 2013 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jul 2013</rights><rights>Macmillan Publishers Limited 2013.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c623t-42af0a02523864a0f74ce8f0010a8288d0f8a630b62ac398c93b3d30987f1bf83</citedby><cites>FETCH-LOGICAL-c623t-42af0a02523864a0f74ce8f0010a8288d0f8a630b62ac398c93b3d30987f1bf83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23615070$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>López-Rodríguez, R</creatorcontrib><creatorcontrib>Hernández-Bartolomé, Á</creatorcontrib><creatorcontrib>Borque, M J</creatorcontrib><creatorcontrib>Rodríguez-Muñoz, Y</creatorcontrib><creatorcontrib>Martín-Vílchez, S</creatorcontrib><creatorcontrib>Trapero-Marugán, M</creatorcontrib><creatorcontrib>García-Buey, L</creatorcontrib><creatorcontrib>Muñoz de Rueda, P</creatorcontrib><creatorcontrib>Rodrigo, L</creatorcontrib><creatorcontrib>Vidal-Castiñeira, J R</creatorcontrib><creatorcontrib>Salmerón, J</creatorcontrib><creatorcontrib>Moreno-Otero, R</creatorcontrib><creatorcontrib>Sanz-Cameno, P</creatorcontrib><title>Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy</title><title>Genes and immunity</title><addtitle>Genes Immun</addtitle><addtitle>Genes Immun</addtitle><description>Histone deacetylases (HDACs) influence many cellular processes, including the modulation of signal transducer and activator of transcription activity (STAT) in response to interferon (IFN). To identify genetic markers that help optimize the
IL-28B
prediction of chronic hepatitis C (CHC) sustained virological response (SVR), we evaluated 27 single-nucleotide polymorphisms (SNPs) in
HDAC1–11
. Three SNPs, rs3778216, rs976552 and rs368328 in
HDAC2
,
HDAC3
and
HDAC5
, respectively, were independently associated with SVR (
P
<0.05). The addition of these three
HDAC’s
SNPs to the
IL-28B
predictive model (area under the curve (AUC)=0.630) rendered an important improvement of AUC-receiver operating characteristic value (AUC=0.747,
P
=0.021). Chi-squared Automatic Interaction Detector (CHAID) analysis denoted the significance of the rs3778216 C/C genotype in identifying a group of good responders despite carrying
IL-28B
T allele (79.2% of SVR), whereas
HDAC5
G allele characterized a subgroup with poor response rate (25.5%). However,
HDAC3
rs976552 did not display a relevant role for the hierarchical classification of patients. Variables related to SVR in hepatitis C virus genotype 1 (HCV-1) cohort were the same of those obtained for the overall population. Interestingly, in non-HCV-1 patients (
n
=56) the
HDAC2
C/C genotype was the unique predictive variable related to SVR (AUC=0.733,
P
<0.007). Thus, these preliminary results suggest the potential usefulness of combined
IL-28B
and
HDAC
genotyping for the CHC patients’ classification by likelihood of an SVR.</description><subject>631/208/248</subject><subject>631/208/721</subject><subject>631/250/255/234/2513/1551</subject><subject>631/326/596/2553</subject><subject>Adult</subject><subject>Aged</subject><subject>Alleles</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Gene Expression</subject><subject>Gene Frequency</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Genetic markers</subject><subject>Genetic polymorphisms</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Genotyping</subject><subject>HDAC2 protein</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - genetics</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Histone deacetylase</subject><subject>Histone Deacetylases - genetics</subject><subject>Histones</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunology</subject><subject>Interferon</subject><subject>Interferon-alpha - chemistry</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferons</subject><subject>Interleukins</subject><subject>Interleukins - genetics</subject><subject>Isoenzymes - genetics</subject><subject>Liver cancer</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>original-article</subject><subject>Patient outcomes</subject><subject>Physiological aspects</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prediction models</subject><subject>Prognosis</subject><subject>Ribavirin - therapeutic use</subject><subject>Single-nucleotide polymorphism</subject><subject>Transcription</subject><subject>Treatment Outcome</subject><subject>Viral Load - drug effects</subject><subject>Viral Load - genetics</subject><subject>Young Adult</subject><issn>1466-4879</issn><issn>1476-5470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9ksuLFDEQxhtR3IfePEvAiwv2mNck6eM6-BgYUHycQyZdmcnS3WmT9OL896aZ9TGySA6pVH715atQVfWM4AXBTL3ewQALiglbUP6gOidcinrJJX44x0LUXMnmrLpI6QZjIohoHldnlAmyxBKfV92n0B36EMe9T31CfkAlyGEA1IKxkA-dSVDy_RjDLaC8BzRGaL3NvhxvTTcBCg6tNzVVb5ALEdl9DIO3aA-jyT77hFZzWTTj4Un1yJkuwdO7_bL69u7t19WHevPx_Xp1vamtoCzXnBqHDaZLypTgBjvJLShX7GOjqFItdsoIhreCGssaZRu2ZS3DjZKObJ1il9XLo24x_X2ClHXvk4WuMwOEKWnCScNEgwUu6It_0JswxaG401RwIpmQxdN_qKJFKVZc8j_UznSg_eBCjsbOT-trVjBBCZ-1FvdQZbXQe1t-3vmSPym4OikoTIYfeWemlPT6y-dT9tWRtTGkFMHpMfrexIMmWM_joudx0fO4aDo7fn7X17Ttof0N_5qPAtRHIJWrYQfxr8bvE_wJwCbF5w</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>López-Rodríguez, R</creator><creator>Hernández-Bartolomé, Á</creator><creator>Borque, M J</creator><creator>Rodríguez-Muñoz, Y</creator><creator>Martín-Vílchez, S</creator><creator>Trapero-Marugán, M</creator><creator>García-Buey, L</creator><creator>Muñoz de Rueda, P</creator><creator>Rodrigo, L</creator><creator>Vidal-Castiñeira, J R</creator><creator>Salmerón, J</creator><creator>Moreno-Otero, R</creator><creator>Sanz-Cameno, P</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7TM</scope><scope>7U9</scope></search><sort><creationdate>20130701</creationdate><title>Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy</title><author>López-Rodríguez, R ; Hernández-Bartolomé, Á ; Borque, M J ; Rodríguez-Muñoz, Y ; Martín-Vílchez, S ; Trapero-Marugán, M ; García-Buey, L ; Muñoz de Rueda, P ; Rodrigo, L ; Vidal-Castiñeira, J R ; Salmerón, J ; Moreno-Otero, R ; Sanz-Cameno, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c623t-42af0a02523864a0f74ce8f0010a8288d0f8a630b62ac398c93b3d30987f1bf83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>631/208/248</topic><topic>631/208/721</topic><topic>631/250/255/234/2513/1551</topic><topic>631/326/596/2553</topic><topic>Adult</topic><topic>Aged</topic><topic>Alleles</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Gene Expression</topic><topic>Gene Frequency</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Genetic markers</topic><topic>Genetic polymorphisms</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Genotyping</topic><topic>HDAC2 protein</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - genetics</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Histone deacetylase</topic><topic>Histone Deacetylases - genetics</topic><topic>Histones</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunology</topic><topic>Interferon</topic><topic>Interferon-alpha - chemistry</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferons</topic><topic>Interleukins</topic><topic>Interleukins - genetics</topic><topic>Isoenzymes - genetics</topic><topic>Liver cancer</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>original-article</topic><topic>Patient outcomes</topic><topic>Physiological aspects</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prediction models</topic><topic>Prognosis</topic><topic>Ribavirin - therapeutic use</topic><topic>Single-nucleotide polymorphism</topic><topic>Transcription</topic><topic>Treatment Outcome</topic><topic>Viral Load - drug effects</topic><topic>Viral Load - genetics</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>López-Rodríguez, R</creatorcontrib><creatorcontrib>Hernández-Bartolomé, Á</creatorcontrib><creatorcontrib>Borque, M J</creatorcontrib><creatorcontrib>Rodríguez-Muñoz, Y</creatorcontrib><creatorcontrib>Martín-Vílchez, S</creatorcontrib><creatorcontrib>Trapero-Marugán, M</creatorcontrib><creatorcontrib>García-Buey, L</creatorcontrib><creatorcontrib>Muñoz de Rueda, P</creatorcontrib><creatorcontrib>Rodrigo, L</creatorcontrib><creatorcontrib>Vidal-Castiñeira, J R</creatorcontrib><creatorcontrib>Salmerón, J</creatorcontrib><creatorcontrib>Moreno-Otero, R</creatorcontrib><creatorcontrib>Sanz-Cameno, P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><jtitle>Genes and immunity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>López-Rodríguez, R</au><au>Hernández-Bartolomé, Á</au><au>Borque, M J</au><au>Rodríguez-Muñoz, Y</au><au>Martín-Vílchez, S</au><au>Trapero-Marugán, M</au><au>García-Buey, L</au><au>Muñoz de Rueda, P</au><au>Rodrigo, L</au><au>Vidal-Castiñeira, J R</au><au>Salmerón, J</au><au>Moreno-Otero, R</au><au>Sanz-Cameno, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy</atitle><jtitle>Genes and immunity</jtitle><stitle>Genes Immun</stitle><addtitle>Genes Immun</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>14</volume><issue>5</issue><spage>317</spage><epage>324</epage><pages>317-324</pages><issn>1466-4879</issn><eissn>1476-5470</eissn><abstract>Histone deacetylases (HDACs) influence many cellular processes, including the modulation of signal transducer and activator of transcription activity (STAT) in response to interferon (IFN). To identify genetic markers that help optimize the
IL-28B
prediction of chronic hepatitis C (CHC) sustained virological response (SVR), we evaluated 27 single-nucleotide polymorphisms (SNPs) in
HDAC1–11
. Three SNPs, rs3778216, rs976552 and rs368328 in
HDAC2
,
HDAC3
and
HDAC5
, respectively, were independently associated with SVR (
P
<0.05). The addition of these three
HDAC’s
SNPs to the
IL-28B
predictive model (area under the curve (AUC)=0.630) rendered an important improvement of AUC-receiver operating characteristic value (AUC=0.747,
P
=0.021). Chi-squared Automatic Interaction Detector (CHAID) analysis denoted the significance of the rs3778216 C/C genotype in identifying a group of good responders despite carrying
IL-28B
T allele (79.2% of SVR), whereas
HDAC5
G allele characterized a subgroup with poor response rate (25.5%). However,
HDAC3
rs976552 did not display a relevant role for the hierarchical classification of patients. Variables related to SVR in hepatitis C virus genotype 1 (HCV-1) cohort were the same of those obtained for the overall population. Interestingly, in non-HCV-1 patients (
n
=56) the
HDAC2
C/C genotype was the unique predictive variable related to SVR (AUC=0.733,
P
<0.007). Thus, these preliminary results suggest the potential usefulness of combined
IL-28B
and
HDAC
genotyping for the CHC patients’ classification by likelihood of an SVR.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23615070</pmid><doi>10.1038/gene.2013.24</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1466-4879 |
| ispartof | Genes and immunity, 2013-07, Vol.14 (5), p.317-324 |
| issn | 1466-4879 1476-5470 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1419369060 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | 631/208/248 631/208/721 631/250/255/234/2513/1551 631/326/596/2553 Adult Aged Alleles Antiviral Agents - therapeutic use Biomedical and Life Sciences Biomedicine Cancer Research Drug Therapy, Combination Female Gastroenterology Gene Expression Gene Frequency Genes Genetic aspects Genetic markers Genetic polymorphisms Genotype Genotype & phenotype Genotyping HDAC2 protein Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - genetics Hepatitis C, Chronic - virology Histone deacetylase Histone Deacetylases - genetics Histones Human Genetics Humans Immune response Immunology Interferon Interferon-alpha - chemistry Interferon-alpha - therapeutic use Interferons Interleukins Interleukins - genetics Isoenzymes - genetics Liver cancer Logistic Models Male Middle Aged Multivariate Analysis original-article Patient outcomes Physiological aspects Polyethylene Glycols - chemistry Polymorphism, Single Nucleotide Prediction models Prognosis Ribavirin - therapeutic use Single-nucleotide polymorphism Transcription Treatment Outcome Viral Load - drug effects Viral Load - genetics Young Adult |
| title | Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T02%3A42%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polymorphisms%20in%20histone%20deacetylases%20improve%20the%20predictive%20value%20of%20IL-28B%20for%20chronic%20hepatitis%20C%20therapy&rft.jtitle=Genes%20and%20immunity&rft.au=L%C3%B3pez-Rodr%C3%ADguez,%20R&rft.date=2013-07-01&rft.volume=14&rft.issue=5&rft.spage=317&rft.epage=324&rft.pages=317-324&rft.issn=1466-4879&rft.eissn=1476-5470&rft_id=info:doi/10.1038/gene.2013.24&rft_dat=%3Cgale_proqu%3EA341262142%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1412208474&rft_id=info:pmid/23615070&rft_galeid=A341262142&rfr_iscdi=true |